Evaxion announces financing commitments totaling up to usd 20 million with negma group

Copenhagen, denmark, aug. 01, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to usd 20 million with negma group investment ltd, a paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.
EVAX Ratings Summary
EVAX Quant Ranking